Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company focused on helping patients who suffer from severe respiratory diseases to breathe better and live life more fully. The company is being purpose-built using our proprietary nitric oxide platform technology. These preclinical assets are licensed from Novan (NASDAQ:NOVN) and were developed in collaboration with Dr. Mark Schoenfisch’s lab at UNC Chapel Hill.
Our technology gives us the unique ability to harness nitric oxide, a chemical compound that plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. By controlling its multiple mechanisms of action, we can create a platform to generate differentiated first-in-class biopolymer/macromolecules that are loaded with nitric oxide and suitable to be inhaled. Our ability to conveniently deploy nitric oxide on demand in an inhaled formulation will allow us to significantly improve patient outcomes in cystic fibrosis and other severe respiratory diseases.
In vitro susceptibility testing against CF related pathogens with our product have been completed and results indicate a broad spectrum of activity and high potency against serious bacterial pathogens.
Most of these pathogens present a significant threat to public health, according to the FDA. Notably, our product has shown susceptibility to Mycobacterium abscessus, which is a growing pathogen among CF patients.